Following her presentation at the ESMO 2019, Dr Noemi Reguart (University of Barcelona) discusses where epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) fit into the treatment of squamous non-small cell lung cancer (NSCLC).
Questions
1. What are the limitations of the current standard of care for squamous non-small cell lung cancer (NSCLC)? (0:04)
2. How prevalent is the epidermal growth factor receptor (EGFR) mutation in squamous NSCLC and in which patient groups is it most commonly found? (5:08)
3. What evidence supports the use of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated squamous NSCLC? (7:36)
4. How can acquired resistance to EGFR TKIs be managed in patients with squamous NSCLC? (10:01)
5. What are the key take home messages of your presentation? (11:09)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosures: Noemi Reguart has acted as an advisor/speaker for MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbvie, Ipsen, Novartis, AstraZeneca, Lilly and Takeda.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
